Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant...
European approval is based on results from the Phase 3 BREAKWATER trial, which demonstrated that encorafenib in combination with cetuximab and mFOLFOX6 demonstrated a statistically significant improvement in the dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS), and a significant overall survival (OS) benefit, reducing the...
Sisram Medical Bolsters EBD and Injectables in Thailand to Unlock APAC Growth
With advancing EBD rollout and steady injectables expansion, integrated treatment protocols deliver unique competitive edges for high-quality regional growth HONG KONG, June 22, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, has officially rolled out its Soprano Titanium across Thailand. Supported by its...
CARsgen Announces Approval of Satri-cel, the World’s First CAR T-Cell Therapy Product for Solid Tumors
SHANGHAI, June 22, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the National Medical Products Administration ("NMPA") today, the New Drug Application ("NDA") of satricabtagene autoleucel ("satri-cel"), the proprietary autologous humanized Claudin18.2 CAR T-cell therapy...
ChemT Biotechnology Raises US$5 Million in 18 months to bring AI to Biomanufacturing
The total funding comprises US$1 million in angel investment and a US$4 million seed round. The seed financing round was led by Wavemaker Ventures, with participation by SEEDS, further supported by notable investors across the United States and Asia. The financing will support the continued expansion of ChemT's AI and experimental infrastructure, which aims to make advanced...
STARTRADER Delivers Emergency Relief to 300 Earthquake-Affected Families in the Philippines
Aid initiative supports families in Sarangani Province following the 7.8-magnitude earthquake, reinforcing the importance of collective action during times of crisis. DUBAI, UAE, June 22, 2026 /PRNewswire/ -- STARTRADER, through its charitable arm STARCARES, is delivering emergency relief to 300 families displaced by the 7.8-magnitude earthquake that struck Sarangani Province in...
Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes. This milestone reflects the Company's long-range quality strategy focused on sustained compliance, continuous audit readiness, and operational effectiveness. Through robust governance, quality...
Innogen Pharmaceutical Group Highlights China-Originated Innovation and Global Development Strategy at DIA Global Annual Meeting 2026 China Town Hall
From original GLP-1 science to international clinical development, Innogen shares its "from 0 to 1" innovation journey in metabolic diseases PHILADELPHIA, June 22, 2026 /PRNewswire/ -- During the DIA Global Annual Meeting 2026 held in Philadelphia, the China Town Hall session was successfully convened, bringing together regulatory, industry and innovation leaders to discuss the development of China's innovative pharmaceutical...
Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI. — The Company is conducting a Phase III registrational study of sac-TMT plus osimertinib as first-line treatment for advanced EGFR-mutant NSCLC (enrollment completed; follow‑up phase) and a Phase II study...
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide, announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates...
FDA Clears PanopticAI’s Contactless Respiratory Rate Measurement
Following the startup's first FDA 510 (k) clearance for its contactless pulse rate monitoring, PanopticAI has now secured a second one for respiratory rate measurement. This milestone cements its position as the world leader in camera-based physiological measurement, bringing the industry closer to a future where clinical-grade health monitoring is accessible to anyone with a smartphone. HONG KONG,...
